# Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

> **NCT03717480** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DEVICE:** ClinicMACs

## Key facts

- **NCT ID:** NCT03717480
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-21
- **Primary completion:** 2021-04-26
- **Final completion:** 2021-04-26
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was prematurely closed to enrollment due to feasibility issues, as the site has promising upcoming competing trials, and the study was already not enrolling at a rate sufficient to meet the accrual goal.
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03717480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03717480, "Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03717480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*